nebulizer

Verona's COPD drug hits goal in phase 3, teeing up FDA filing

Verona has hit the mark in its first of two phase 3 COPD trials, keeping it on course to file for FDA approval of the inhaled PDE3 and PDE4 inhibitor.

Nick Paul Taylor Aug 9, 2022 6:40am